Search | Proceedings | Concurrent Oral Session Grid | Author Index | eBook

Author Index: M

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Madarnas, Y.
P2-28   DECISION SUPPORT NEEDS TO BE TAILORED TO THE INDIVIDUAL PATIENT: ADJUVANT ENDOCRINE THERAPY FOR POST-MENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE EARLY-STAGE BREAST CANCER
Magid, D. J.
P2-20   MEASURING PREFERENCES AROUND MODES OF DEATH, THE CASE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
Maillart, L.
P2-37   DYNAMICALLY OPTIMIZING THE ADMINISTRATION OF VACCINES FROM MULTI-DOSE VIALS
Makarov, D. V.
P3-4   USING SOCIAL MEDIA TO GAUGE REACTION TO THE USPSTF REPORT ON PROSTATE CANCER SCREENING: TWITTER AS AN INVESTIGATIVE TOOL
Malhotra, S.
TRA1-1   IMPROVING PHYSICIAN PRESCRIBING DECISIONS THROUGH USER INTERFACE REDESIGN
Mann, M.
P3-1   THE IMPLEMENTATION OF PATIENT DECISION SUPPORT INTERVENTIONS INTO ROUTINE CLINICAL PRACTICE: A SYSTEMATIC REVIEW
Mao, L.
P3-20   A TALE OF TWO TRIAL DESIGNS: EVALUATION OF EFFICACY VS EFFECTIVENESS IN SCHIZOPHRENIA
Marang-van de Mheen, P. J.
P3-17   DO STARS HELP PATIENTS TO CHOOSE A HOSPITAL FOR SURGERY? A HOSPITAL CHOICE EXPERIMENT,
P4-20   BARRIERS AND FACILITATORS TO IMPLEMENT SHARED DECISION MAKING IN TREATMENT OF SCIATICA PATIENTS
Marascalchi, B. J.
P3-51   PATIENT DISCORDANCE BETWEEN SURGERY CHOICE AND TREATMENT-RELATED VALUES: A PRELIMINARY STUDY OF BARIATRIC PATIENTS
Markham, M. J.
P1-30   LONG-TERM BREAST CANCER SURVIVORS' PERCEPTIONS OF CANCER RISK: A MENTAL MODELS STUDY
Markow, C.
H-1   INFORMING CONSUMERS CHOICE OF HIGH QUALITY FACILITIES FOR ELECTIVE SURGERY: COMPARING HEALTH PLAN CENTERS-OF-EXCELLENCE DESIGNATIONS WITH PUBLICLY REPORTED QUALITY METRICS
Marquez, J. L. S.
P3-19   AN ONLINE TRANSPARENCY PLATFORM ENABLES PREFERENCE-APPROPRIATE BEHAVIOR CHANGE FOR CONSUMERS ON A REFERENCE-BASED PRICING BENEFIT PLAN
Marshall, D.
K-6   COST-EFFECTIVENESS OF METAL-ON-METAL HIP RESURFACING COMPARED TO CONVENTIONAL TOTAL HIP ARTHROPLASTY
Marsteller, J. A.
P2-21   FACTORS IMPACTING STAKEHOLDERS' MOTIVATION FOR IMPLEMENTING NATIONAL LIVER CANCER CONTROL PLANS IN 12 COUNTRIES
Martin, S.
P3-29   PATIENT-REPORTED SATISFACTION ON USTEKINUMAB TREATMENT COMPARED WITH PRIOR BIOLOGIC THERAPY,
P4-26   UTILIZATION OF USTEKINUMAB IN BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAïVE PSORIASIS PATIENTS
Martins, S. B.
P3-39   STAKEHOLDER INPUT TO CLINICAL DECISION SUPPORT (CDS) FOR COMPLEX CHRONIC DISEASE
Mason, J. E.
P1-47   OPTIMIZATION OF HYPERGLYCEMIA TREATMENT INTENSIFICATION FOR PATIENTS WITH TYPE 2 DIABETES
Masoudi, F.
P2-20   MEASURING PREFERENCES AROUND MODES OF DEATH, THE CASE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
Mates, M.
P2-28   DECISION SUPPORT NEEDS TO BE TAILORED TO THE INDIVIDUAL PATIENT: ADJUVANT ENDOCRINE THERAPY FOR POST-MENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE EARLY-STAGE BREAST CANCER
Matesic, B.
P1-34   COST-EFFECTIVENESS OF TREATMENT OPTIONS FOR DIABETIC MACULAR EDEMA
Mathew, S.
P4-50   USING DISASTER PREPAREDNESS PRINCIPLES TO IMPROVE MEDICAL EDUCATION AND HEALTH CARE PERFORMANCE OUTCOMES
Mathews, K. S.
P1-36   CHARACTERIZING THE FLOW OF SHORT-STAY PATIENTS IN THE INTENSIVE CARE UNIT
Mathur, M.
P1-35   PROGNOSTIC MODEL OF MORTALITY FOLLOWING HUMAN INFLUENZA (A) H5N1 INFECTION
Matlock, D. D.
A-5   PHYSICIAN INNUMERACY IS ASSOCIATED WITH MORE ENTHUSIASM FOR CANCER SCREENING,
P2-20   MEASURING PREFERENCES AROUND MODES OF DEATH, THE CASE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
Matza, L.
P3-13   IMPACT OF CAREGIVER STATUS ON HEALTH STATE VALUATIONS
Max, W.
P1-32   MODELING THE ADDED PREDICTIVE VALUE OF A NOVEL CARDIOVASCULAR RISK MARKER WITH A SIMPLE MARKOV MODEL,
P2-51   ITERATIVE CALIBRATION OF MONTE-CARLO MARKOV MODELS USED FOR EVALUATING THE IMPACT OF UPDATING TRADITIONAL CARDIOVASCULAR RISK PREDICTIONS WITH NOVEL RISK MARKERS
McBroom, A. J.
P1-40   NET EFFECT OF CURRENT PATTERNS OF ORAL CONTRACEPTIVE USE ON POTENTIALLY FATAL OUTCOMES IN THE UNITED STATES,
P1-41   USING NET BENEFITS AND ACCEPTABILITY CURVES TO QUANTIFY UNCERTAINTY ABOUT TRADEOFFS BETWEEN HARMS AND BENEFITS OF ORAL CONTRACEPTIVES
McCaffery, K.
A-2   WOMEN'S RESPONSES TO INFORMATION ABOUT OVERDIAGNOSIS IN MAMMOGRAPHY SCREENING,
P2-31   RCT OF MCDA TO PERSONALISE PREVENTIVE HEALTH DECISIONS
McCarron, C. E.
E-4   COST EFFECTIVENESS OF STEREOTACTIC BODY RADIATION THERAPY FOR MEDICALLY OPERABLE STAGE I NON–SMALL CELL LUNG CANCER
McDaniel, K.
P3-13   IMPACT OF CAREGIVER STATUS ON HEALTH STATE VALUATIONS
McMahon, P.
B-1   OPTIMIZATION OF FOLLOW-UP GUIDELINES FOR CLINICAL MANAGEMENT OF PULMONARY NODULES USING A LUNG CANCER MODEL,
L-5   COST-EFFECTIVENESS OF SCREENING RESISTANT HYPERTENSIVE PATIENTS FOR PRIMARY ALDOSTERONISM
Melnikow, J.
P2-12   DEVELOPMENT AND EVALUATION OF AN ANALYTICAL POLICY TOOL
Melstrom, E.
P4-30   ILLOGICAL RESPONSES FOR JOINT HEALTH STATE UTILITIES; A COMPARISON OF TIME-TRADEOFFS AND STANDARD GAMBLE METHODS
Menko, F. H.
P4-47   DOES TIME FRAME MATTER? COMMUNICATING AGE-RELATED OR LIFETIME RISKS IN BREAST CANCER RISK COMMUNICATION
Menzies, N. A.
TRA2-2   ESTIMATING THE COST-EFFECTIVENESS OF XPERT MTB/RIF: APPLYING A BAYESIAN CALIBRATION APPROACH TO A DYNAMIC TB-HIV EPIDEMIC MODEL
Meslin, E. M.
G-3   PARENTS' ATTITUDES ABOUT THE USE OF RESIDUAL NEWBORN BLOOD SPOTS FOR RESEARCH
Metcalf, S. K.
P3-19   AN ONLINE TRANSPARENCY PLATFORM ENABLES PREFERENCE-APPROPRIATE BEHAVIOR CHANGE FOR CONSUMERS ON A REFERENCE-BASED PRICING BENEFIT PLAN
Meurer, W.
P4-37   ECONOMIC BENEFIT OF AN EDUCATIONAL INTERVENTION TO IMPROVE TPA USE IN COMMUNITY HOSPITALS
Michaud, K. D.
P1-3   IMPLICATIONS OF USING EFFECTIVENESS INSTEAD OF EFFICACY ON THE COST-EFFECTIVENESS OF BIOLOGICS IN RHEUMATOID ARTHRITIS: A MULTI-STUDY SENSITIVITY ANALYSIS,
P3-16   WHEN AND FOR WHOM ARE BIOLOGICS COST-EFFECTIVE IN RHEUMATOID ARTHRITIS?
Migliaccio-Walle, K.
P2-47   COMPARATIVE EFFECTIVENESS AND SAFETY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN DIABETIC MACULAR EDEMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EVIDENCE
Miller, K. D.
P3-41   DOES UNBLINDING OF TREATMENT ASSIGNMENT IMPACT PARTICIPANT PERCEPTIONS IN CLINICAL TRIALS?
Mills, E. J.
H-4   WHY THE FINDINGS OF PUBLISHED BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS MULTIPLE TREATMENT COMPARISON META-ANALYSES ARE DIFFERENT: AN OVERVIEW OF RECURRENT METHODOLOGICAL SHORTCOMINGS
Mirkin, J. N.
P3-37   THE ECONOMIC IMPACT OF ROBOTIC AND OPEN RADICAL PROSTATECTOMY ON PATIENTS AND THEIR FAMILIES
Mirza, S.
D-6   DOES HEALTH COACHING AFFECT THE DECISION PROCESS FOR PATIENTS CHOOSING A SPINAL STENOSIS TREATMENT?
Mishra, S.
F-2   SCREEN MORE OR SCREEN MORE OFTEN? USING MATHEMATICAL MODELS TO INFORM SYPHILIS CONTROL STRATEGIES
Mission, J. F.
P4-31   TREATING PATIENTS IN HAPO GLUCOSE CATEGORY 5 TO IMPROVE MATERNAL AND NEONATAL OUTCOMES: A COST EFFECTIVENESS ANALYSIS
Mitchell, D.
H-2   META-ANALYSIS OF REAL-WORLD STUDIES OF INITIATING INSULIN GLARGINE VIA DISPOSABLE PEN VERSUS VIAL/SYRINGE AMONG PATIENTS WITH TYPE 2 DIABETES: APPLYING A COMMON DATA STRUCTURE TO A UNIQUE EVIDENCE SYNTHESIS PLATFORM
Mitchell, S. E.
P4-34   DEVELOPING VIRTUAL PATIENT ADVOCATE TECHNOLOGY FOR SHARED DECISION MAKING
Modave, F. P.
P1-54   NON-ADDITIVE MEASURES IN MEDICAL DECISION MAKING
Mofrad, M.
P2-37   DYNAMICALLY OPTIMIZING THE ADMINISTRATION OF VACCINES FROM MULTI-DOSE VIALS
Mofrad, M. H.
P1-51   COST-EFFECTIVENESS ANALYSIS WITH MARKOV DECISION PROCESSES
Mollon, L.
P3-30   ASSESSING HEALTHCARE PROVIDER SATISFACTION OF SERVICES PROVIDED BY THE ARIZONA REGIONAL EXTENSION CENTER (REC): A CROSS-SECTIONAL SURVEY
Monane, M.
B-4   REFERRAL BIAS IN THE DIAGNOSTIC PERFORMANCE OF EXERCISE TESTING WITH IMAGING FOR CORONARY ARTERY DISEASE,
P4-3   COST EFFECTIVENESS OF A GENE EXPRESSION SCORE AND MYOCARDIAL PERFUSION IMAGING FOR DIAGNOSIS OF CORONARY ARTERY DISEASE
Mooney, A.
D-1   TESTING THE ADDED VALUE OF DECISION AID COMPONENTS TO FACILITATE PATIENTS INFORMED DECISION MAKING ABOUT DIALYSIS TREATMENT OPTIONS
Moons, K. G. M.
C-1   DON'T USE A LOT WHERE A LITTLE WILL DO: A MINIMAL INFORMATION DECISION-ANALYTIC APPROACH TO EARLY HTA OF DIAGNOSTIC TESTS
Moorman, P. G.
P1-40   NET EFFECT OF CURRENT PATTERNS OF ORAL CONTRACEPTIVE USE ON POTENTIALLY FATAL OUTCOMES IN THE UNITED STATES,
P1-41   USING NET BENEFITS AND ACCEPTABILITY CURVES TO QUANTIFY UNCERTAINTY ABOUT TRADEOFFS BETWEEN HARMS AND BENEFITS OF ORAL CONTRACEPTIVES
Morath, J. M.
TRA2-1   REAL-TIME PREDICTIVE MODELING TO STRATIFY RISK FOR ALL ADULT INPATIENTS TO REDUCE HOSPITAL READMISSIONS
Morgan DeWitt, E.
P2-25   PROVIDER PERSPECTIVES ON DECISION-MAKING IN JUVENILE IDIOPATHIC ARTHRITIS
Morlan, B. W.
P4-38   METHODS FOR EVALUATING STRATEGIES FOR RAPID RESPONSE TEAMS IN HOSPITAL SETTINGS
Morrissey, J.
P1-31   IDENTIFYING FACTORS ASSOCIATED WITH STATE PSYCHIATRIC HOSPITAL USE TO INFORM ADMISSION, REFERRAL, AND POLICY DECISION-MAKING
Motley, C.
P3-41   DOES UNBLINDING OF TREATMENT ASSIGNMENT IMPACT PARTICIPANT PERCEPTIONS IN CLINICAL TRIALS?
Mouton, C. P.
D-5   NOVEL METHODS TO OVERCOME HEALTH LITERACY BARRIERS TO SHARED DECISION MAKING IN PROSTATE CANCER AMONG LOW-INCOME AFRICAN AMERICAN MEN
Mullins, C. D.
P1-39   PATTERNS AND CORRELATES OF LINKAGE TO APPROPRIATE HIV CARE FOLLOWING HIV DIAGNOSIS IN THE UNITED STATES MEDICAID POPULATION
Munir, K.
P1-5   THE ECONOMIC BURDEN OF CHILDHOOD AUTISM SPECTRUM DISORDERS,
P3-47   PARENT AND CHILD HEALTH UTILITIES ASSOCIATED WITH AUTISM SPECTRUM DISORDERS
Munro, E.
P3-48   TIMING DELIVERY OF PLACENTA ACCRETA: A DECISION ANALYSIS
Munshi, V.
B-1   OPTIMIZATION OF FOLLOW-UP GUIDELINES FOR CLINICAL MANAGEMENT OF PULMONARY NODULES USING A LUNG CANCER MODEL
Murphy, J.
K-1   THE COST-EFFECTIVENESS OF INTEGRATED CERVICAL CANCER PREVENTION STRATEGIES IN THE ONTARIO SETTING – CAN WE DO BETTER?
Murray, M.
TRA2-2   ESTIMATING THE COST-EFFECTIVENESS OF XPERT MTB/RIF: APPLYING A BAYESIAN CALIBRATION APPROACH TO A DYNAMIC TB-HIV EPIDEMIC MODEL
Murtagh Kurowski, E.
P1-1   COST-EFFECTIVENESS OF FOUR DIFFERENT STRATEGIES FOR EVALUATION OF FEVER IN INFANTS LESS THAN 60 DAYS OF AGE
Mushlin, A. I.
L-6   COST-EFFECTIVENESS OF BLOOD DONOR SCREENING FOR BABESIOSIS IN ENDEMIC REGIONS
Myers, E. R.
P1-40   NET EFFECT OF CURRENT PATTERNS OF ORAL CONTRACEPTIVE USE ON POTENTIALLY FATAL OUTCOMES IN THE UNITED STATES,
P1-41   USING NET BENEFITS AND ACCEPTABILITY CURVES TO QUANTIFY UNCERTAINTY ABOUT TRADEOFFS BETWEEN HARMS AND BENEFITS OF ORAL CONTRACEPTIVES,
P2-7   SURVEILLANCE GUIDELINES FOR LOW GRADE NON-INVASIVE BLADDER CANCER: A COST COMPARISON
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z